Wealth Enhancement Advisory Services’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$336K	Sell	68,816 -9,924	-13%	-$39.6K	﹤0.01%	3092
2026 Q1	$207K	Sell	78,740 -51,667	-40%	-$133K	﹤0.01%	3108
2025 Q4	$232K	Sell	130,407 -35,883	-22%	-$52.2K	﹤0.01%	3148
2025 Q3	$258K	Sell	166,290 -7,716	-4%	-$11.6K	﹤0.01%	2912
2025 Q2	$219K	Sell	174,006 -60,065	-26%	-$79.2K	﹤0.01%	2908
2025 Q1	$372K	Buy	234,071 +33,958	+17%	+$73.2K	﹤0.01%	2270
2024 Q4	$606K	Buy	200,113 +132,220	+195%	+$433K	﹤0.01%	1843
2024 Q3	$250K	Buy	67,893 +20,848	+44%	+$75.8K	﹤0.01%	2304
2024 Q2	$192K	Buy	47,045 +3,870	+9%	+$43.2K	﹤0.01%	2309
2024 Q1	$680K	Buy	+43,175	New	+$594K	﹤0.01%	1411

Other funds holding ZNTL

MAM

Marquette Asset Management Minneapolis, Minnesota $779M AUM 23.4% 1-Year Est. Return

Wealth Enhancement Advisory Services's ZNTL Position: Q2 2026 in Review

Wealth Enhancement Advisory Services reduced its Zentalis Pharmaceuticals (ZNTL) stake by 13% in Q2 2026, selling an estimated $39.6K and leaving 68,816 shares worth $336K. The position accounts for ﹤0.01% of the portfolio, ranked #3092.

Wealth Enhancement Advisory Services first reported a position in ZNTL in Q1 2024 and has held it in 10 quarters since. The position peaked at $680K in Q1 2024. 2 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

Wealth Enhancement Advisory Services held 68,816 shares of Zentalis Pharmaceuticals worth $336K as of Q2 2026.
Wealth Enhancement Advisory Services sold 9,924 Zentalis Pharmaceuticals shares in Q2 2026, an estimated $39.6K.
Zentalis Pharmaceuticals made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #3092 holding.
Wealth Enhancement Advisory Services first reported a position in Zentalis Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
Wealth Enhancement Advisory Services's Zentalis Pharmaceuticals position peaked at $680K in Q1 2024.
2 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.